What is HC Wainwright’s Estimate for ROIV FY2026 Earnings?

Roivant Sciences Ltd. (NASDAQ:ROIV) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Roivant Sciences in a research note issued to investors on Tuesday, February 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($1.55) for the year, up from their previous estimate of ($1.61). HC Wainwright currently has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Roivant Sciences’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.79) EPS.

A number of other analysts have also recently issued reports on ROIV. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research note on Saturday, February 7th. Guggenheim raised their target price on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday. Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group reissued a “buy” rating and set a $30.00 target price on shares of Roivant Sciences in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.69.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $26.75 on Friday. The business has a 50-day moving average of $22.60 and a two-hundred day moving average of $18.20. The firm has a market capitalization of $18.60 billion, a PE ratio of -22.86 and a beta of 1.22. Roivant Sciences has a 12 month low of $8.73 and a 12 month high of $27.94.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ROIV. Vanguard Group Inc. boosted its position in shares of Roivant Sciences by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after purchasing an additional 3,254,113 shares in the last quarter. Rubric Capital Management LP lifted its stake in Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. State Street Corp boosted its holdings in Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after buying an additional 911,827 shares in the last quarter. UBS Group AG grew its position in Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after buying an additional 15,645,836 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Richard Pulik sold 406,731 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total value of $9,122,976.33. Following the transaction, the chief financial officer owned 239,413 shares of the company’s stock, valued at $5,370,033.59. This trade represents a 62.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 11,156,880 shares of company stock worth $244,463,758 over the last three months. Insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.